Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shandong Xinhua Pharmaceutical Company Limited (000756.SZ)
Zibo, CN
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. It also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, the company offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate leasing, and housing leasing activities; certification and import and export business; electrical equipment engineering; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.21% | -5.11% | -6.17% | -15.74% | -23.85% | -13.17% | -11.39% | -43.62% | +48.67% | +69.58% | +44.96% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+3.3% Q1'26: -0.3% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%-38.2% Q1'26: -20.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-2.3% Q1'26: -5.9% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+4.0% Q1'26: +5.1% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+4.9% Q1'26: +5.6% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.1% Q1'26: -6.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×5.80× Q1'26: 3.90× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.01B
est: 3.68B (+9.1%)
|
4.52B
est: 4.72B (-4.3%)
|
5.24B
est: 5.21B (+0.7%)
|
5.61B
est: 5.23B (+7.3%)
|
6.01B
est: 3.68B (+63.3%)
|
6.56B
est: 4.72B (+39.0%)
|
7.50B
est: 5.21B (+44.1%)
|
8.10B
est: 5.23B (+55.0%)
|
8.47B
est: 8.33B (+1.6%)
|
8.74B
est: 8.73B (+0.1%)
|
9.35B
9.35B – 9.35B
+7.0% YoY
|
9.88B
9.88B – 9.88B
+5.7% YoY
|
8.33B
8.33B – 8.33B
-15.7% YoY
|
9.18B
9.18B – 9.18B
+10.2% YoY
|
9.83B
9.83B – 9.83B
+7.0% YoY
|
| EBITDA |
447.00M
est: 475.28M (-5.9%)
|
582.92M
est: 609.62M (-4.4%)
|
667.23M
est: 672.89M (-0.8%)
|
734.07M
est: 675.36M (+8.7%)
|
842.97M
est: 475.28M (+77.4%)
|
840.20M
est: 609.62M (+37.8%)
|
952.48M
est: 672.89M (+41.6%)
|
1.03B
est: 675.36M (+52.0%)
|
1.05B
est: 908.68M (+15.5%)
|
346.34M
est: 952.52M (-63.6%)
|
1.02B
1.02B – 1.02B
+7.0% YoY
|
1.08B
1.08B – 1.08B
+5.7% YoY
|
908.68M
908.68M – 908.68M
-15.7% YoY
|
1.00B
1.00B – 1.00B
+10.2% YoY
|
1.07B
1.07B – 1.07B
+7.0% YoY
|
| EBIT |
191.15M
est: 238.03M (-19.7%)
|
299.45M
est: 305.32M (-1.9%)
|
361.20M
est: 337.00M (+7.2%)
|
390.33M
est: 338.24M (+15.4%)
|
458.77M
est: 238.03M (+92.7%)
|
403.67M
est: 305.32M (+32.2%)
|
465.87M
est: 337.00M (+38.2%)
|
512.15M
est: 338.24M (+51.4%)
|
510.63M
est: 477.89M (+6.8%)
|
346.34M
est: 500.95M (-30.9%)
|
536.17M
536.17M – 536.17M
+7.0% YoY
|
566.66M
566.66M – 566.66M
+5.7% YoY
|
477.89M
477.89M – 477.89M
-15.7% YoY
|
526.65M
526.65M – 526.65M
+10.2% YoY
|
563.62M
563.62M – 563.62M
+7.0% YoY
|
| Net Income |
122.27M
est: 122.41M (-0.1%)
|
209.59M
est: 287.12M (-27.0%)
|
255.31M
est: 276.48M (-7.7%)
|
299.97M
est: 430.68M (-30.4%)
|
324.86M
est: 122.41M (+165.4%)
|
348.55M
est: 287.12M (+21.4%)
|
411.06M
est: 276.48M (+48.7%)
|
496.51M
est: 430.68M (+15.3%)
|
470.02M
est: 456.47M (+3.0%)
|
289.89M
est: 435.72M (-33.5%)
|
650.12M
650.12M – 650.12M
+49.2% YoY
|
677.79M
677.79M – 677.79M
+4.3% YoY
|
456.47M
456.47M – 456.47M
-32.7% YoY
|
504.88M
504.88M – 504.88M
+10.6% YoY
|
574.04M
574.04M – 574.04M
+13.7% YoY
|
| SGA |
725.52M
est: 533.56M (+36.0%)
|
729.30M
est: 684.37M (+6.6%)
|
923.18M
est: 755.40M (+22.2%)
|
1.10B
est: 758.17M (+45.7%)
|
943.96M
est: 533.56M (+76.9%)
|
929.12M
est: 684.37M (+35.8%)
|
1.11B
est: 755.40M (+46.4%)
|
1.29B
est: 758.17M (+69.8%)
|
1.02B
est: 1.10B (-7.5%)
|
804.10M
est: 1.15B (-30.3%)
|
1.23B
1.23B – 1.23B
+7.0% YoY
|
1.30B
1.30B – 1.30B
+5.7% YoY
|
1.10B
1.10B – 1.10B
-15.7% YoY
|
1.21B
1.21B – 1.21B
+10.2% YoY
|
1.30B
1.30B – 1.30B
+7.0% YoY
|
| EPS |
0.21
est: 0.18 (+17.3%)
|
0.35
est: 0.42 (-15.7%)
|
0.41
est: 0.40 (+2.7%)
|
0.48
est: 0.62 (-23.0%)
|
0.52
est: 0.18 (+193.6%)
|
0.56
est: 0.42 (+34.8%)
|
0.62
est: 0.40 (+55.0%)
|
0.74
est: 0.62 (+18.8%)
|
0.69
est: 0.66 (+4.5%)
|
0.42
est: 0.63 (-33.3%)
|
0.94
0.94 – 0.94
+49.2% YoY
|
0.98
0.98 – 0.98
+4.3% YoY
|
0.66
0.66 – 0.66
-32.7% YoY
|
0.73
0.73 – 0.73
+10.6% YoY
|
0.83
0.83 – 0.83
+13.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P China ETF GXC | 0.01% | 55.1K | 0.59% |
| 2 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.01% | 51.1K | 0.49% |
| 3 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.01% | 1.30M | 0.07% |
| 4 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 39.5K | 0.65% |
| 5 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 240.4K | 0.06% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 7.8K | 0.48% |
| 7 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 17.6K | 0.26% |
| 8 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 866.4K | 0.06% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.00% | 11.1K | 0.10% |
| 10 | Vanguard Total International Stock ETF VXUS | 0.00% | 924.3K | 0.05% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Tongqing He | Executive Chairman | 2M | male |
| Wenhui Xu | GM & Executive Director | 2M | male |
| Ning Hou | Chief Financial Officer & Executive Director | 2M | male |
| Xuesong Liu | Deputy General Manager | — | male |
| Zhonghui Zheng | Deputy General Manager | — | male |
| Changqiu Cao | Company Secretary | — | male |
| Zuxing Kou | Deputy General Manager | — | male |
| Changsheng Wei | Deputy GM & Manager of the Administrative Personnel Department | — | male |
| Xiaohong He | Head of Accounting Department | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 000756.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
